Literature DB >> 19652083

Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors?

Joey P Granger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19652083      PMCID： PMC2759752          DOI： 10.1161/HYPERTENSIONAHA.109.132274

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  15 in total

Review 1.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

2.  Preeclampsia pathogenesis: "triple a rating"-autoantibodies and antiangiogenic factors.

Authors:  S Ananth Karumanchi; Marshall D Lindheimer
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

Review 3.  Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia.

Authors:  Babbette D LaMarca; Jeffery Gilbert; Joey P Granger
Journal:  Hypertension       Date:  2008-02-07       Impact factor: 10.190

Review 4.  Role of endothelin-1 in clinical hypertension: 20 years on.

Authors:  Neeraj Dhaun; Jane Goddard; Donald E Kohan; David M Pollock; Ernesto L Schiffrin; David J Webb
Journal:  Hypertension       Date:  2008-08-04       Impact factor: 10.190

Review 5.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

Review 6.  Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions.

Authors:  Eva H C Tang; Paul M Vanhoutte
Journal:  Pharmacol Ther       Date:  2009-03-12       Impact factor: 12.310

7.  Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression.

Authors:  Carie S Facemire; Andrew B Nixon; Robert Griffiths; Herbert Hurwitz; Thomas M Coffman
Journal:  Hypertension       Date:  2009-08-03       Impact factor: 10.190

Review 8.  Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Kathleen Stergiopoulos; Shenhong Wu
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

9.  Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism.

Authors:  Agnes Machnik; Wolfgang Neuhofer; Jonathan Jantsch; Anke Dahlmann; Tuomas Tammela; Katharina Machura; Joon-Keun Park; Franz-Xaver Beck; Dominik N Müller; Wolfgang Derer; Jennifer Goss; Agata Ziomber; Peter Dietsch; Hubertus Wagner; Nico van Rooijen; Armin Kurtz; Karl F Hilgers; Kari Alitalo; Kai-Uwe Eckardt; Friedrich C Luft; Dontscho Kerjaschki; Jens Titze
Journal:  Nat Med       Date:  2009-05-03       Impact factor: 53.440

10.  Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.

Authors:  Andrew Advani; Darren J Kelly; Suzanne L Advani; Alison J Cox; Kerri Thai; Yuan Zhang; Kathryn E White; Renae M Gow; Sally M Marshall; Brent M Steer; Philip A Marsden; P Elizabeth Rakoczy; Richard E Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205
View more
  8 in total

Review 1.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

Authors:  Emily S Robinson; Eliyahu V Khankin; S Ananth Karumanchi; Benjamin D Humphreys
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

2.  Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.

Authors:  Emily S Robinson; Eliyahu V Khankin; Toni K Choueiri; Mallika S Dhawan; Miranda J Rogers; S Ananth Karumanchi; Benjamin D Humphreys
Journal:  Hypertension       Date:  2010-10-18       Impact factor: 10.190

Review 3.  Intravitreal Anti-VEGF Injections in Pregnancy: Case Series and Review of Literature.

Authors:  Silvio Polizzi; Vinit B Mahajan
Journal:  J Ocul Pharmacol Ther       Date:  2015-08-24       Impact factor: 2.671

4.  Complications of combined retinal and retinal pigment epithelium hamartoma involving the optic disc in a child, treated with Avastin - a review of the literature and case presentation.

Authors:  Cormos Diana
Journal:  Rom J Ophthalmol       Date:  2015 Oct-Dec

Review 5.  Adipose Tissue and Modulation of Hypertension.

Authors:  Eashita Das; Joon Ho Moon; Ju Hee Lee; Nikita Thakkar; Zdenka Pausova; Hoon-Ki Sung
Journal:  Curr Hypertens Rep       Date:  2018-09-18       Impact factor: 5.369

6.  The effects of A2B receptor modulators on vascular endothelial growth factor and nitric oxide axis in chronic cyclosporine nephropathy.

Authors:  Leena Patel; Aswin Thaker
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

7.  Folic acid mitigates angiotensin-II-induced blood pressure and renal remodeling.

Authors:  Sathnur B Pushpakumar; Sourav Kundu; Naira Metreveli; Utpal Sen
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

8.  A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors.

Authors:  Ingrid Brænne; Christina Willenborg; Vinicius Tragante; Thorsten Kessler; Lingyao Zeng; Benedikt Reiz; Mariana Kleinecke; Simon von Ameln; Cristen J Willer; Markku Laakso; Philipp S Wild; Tanja Zeller; Lars Wallentin; Paul W Franks; Veikko Salomaa; Abbas Dehghan; Thomas Meitinger; Nilesh J Samani; Folkert W Asselbergs; Jeanette Erdmann; Heribert Schunkert
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.